Abstract | AIMS: METHODS: Published papers related to the mechanism of action of approved osteoporosis treatments were sought through MEDLINE searches. FINDINGS:
Osteoporotic fractures carry a substantial burden of morbidity and mortality, but pharmacotherapy can prevent such fractures in high-risk individuals. Antiresorptive drugs (e.g. bisphosphonates, oestrogen, denosumab) reduce bone turnover by distinct mechanisms. Denosumab, a recently approved therapy, is a fully human monoclonal antibody that binds the cytokine RANKL (receptor activator of NFκB ligand), an essential factor initiating bone turnover. RANKL inhibition blocks osteoclast maturation, function and survival, thus reducing bone resorption. In contrast, bisphosphonates bind bone mineral, where they are absorbed by mature osteoclasts, inducing osteoclast apoptosis and suppressing resorption. These differences in mechanism influence both the onset and reversibility of treatment. DISCUSSION:
|
Authors | D A Hanley, J D Adachi, A Bell, V Brown |
Journal | International journal of clinical practice
(Int J Clin Pract)
Vol. 66
Issue 12
Pg. 1139-46
(Dec 2012)
ISSN: 1742-1241 [Electronic] India |
PMID | 22967310
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Copyright | © 2012 Blackwell Publishing Ltd. |
Chemical References |
- Antibodies, Monoclonal, Humanized
- Bone Density Conservation Agents
- Diphosphonates
- Teriparatide
- Denosumab
|
Topics |
- Antibodies, Monoclonal, Humanized
(pharmacology, therapeutic use)
- Bone Density Conservation Agents
(pharmacology, therapeutic use)
- Bone Remodeling
(drug effects)
- Denosumab
- Diphosphonates
(pharmacology)
- Humans
- Male
- Middle Aged
- Osteoporosis, Postmenopausal
(drug therapy)
- Osteoporotic Fractures
(prevention & control)
- Practice Guidelines as Topic
- Teriparatide
(pharmacology)
|